Showing 1811-1820 of 2123 results for "".
- Wearable Bladder Monitoring Device May Help Predict UTIs in Women With MShttps://practicalneurology.com/news/wearable-bladder-monitoring-device-may-help-predict-utis-in-women-with-ms/2474951/At the 2025 Annual Meeting of The Consortium of Multiple Sclerosis Centers (CMSC), researchers presented promising data on the use of wearable ultrasound (US) technology to monitor urinary retention in women with multiple sclerosis (MS). The study evaluated the use of the DFree device (Dfree; Sa
- FDA Authorizes First Prescription Digital Therapeutic for Preventing Episodic Migrainehttps://practicalneurology.com/news/fda-authorizes-first-prescription-digital-therapeutic-for-preventing-episodic-migraine/2474512/The Food and Drug Administration (FDA) has granted marketing authorization to CT-132, a prescription digital therapeutic developed by Click Therapeutics (New York, NY), for the preventive treatment of episodic migraine in adults. CT-132 is the first FDA-authorized prescription digital therapeutic
- Neurostimulation Device for Drug-Resistant Focal Epilepsy Demonstrates Significant, Long-Term Reductions in Seizureshttps://practicalneurology.com/news/neurostimulation-device-for-drug-resistant-focal-epilepsy-demonstrates-significant-long-term-reductions-in-seizures/2474345/Three-year data from a post-approval study (PAS; NCT02403843) of the NeuroPace Responsive Neurostimulation (RNS) System (Mountain View, CA) demonstrated significant and sustained reductions in seizures in adults with drug-resistant focal epilepsy (DRE). The results of the PAS presented at the Ame
- FDA Clears Brain–Computer Interface Device for the Measurement and Stimulation of Cortical Brain Activityhttps://practicalneurology.com/news/fda-clears-braincomputer-interface-device-for-the-measurement-and-stimulation-of-cortical-brain-activity/2474229/The Food and Drug Administration (FDA) has granted 510(k) clearance to the Layer 7 Cortical Interface device (Precision Neuroscience, New York Ci
- Substantially Higher Mortality Risk Demonstrated for Children and Adolescents with Severe Epilepsy and Sleep Apneahttps://practicalneurology.com/news/substantially-higher-mortality-risk-demonstrated-for-children-and-adolescents-with-severe-epilepsy-and-sleep-apnea/2474009/Study results presented at the American Academy of Neurology (AAN) 2025 Annual Meeting demonstrate that central sleep apnea (CSA) and other sleep apnea, including obstructive sleep apnea (OSA), are associated with an increased risk of mortality in children and adolescents aged 1 to 17 years with
- Norepinephrine Reuptake Inhibitor Treatment Significantly Reduced Cataplexy Attacks in People with Narcolepsy Type 1https://practicalneurology.com/news/nri-therapy-significantly-reduced-cataplexy-attacks-in-people-with-narcolepsy-type-1/2473965/Treatment with AXS-12 (reboxetine; Axsome, New York, NY), a highly selective norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator, was associated with significant reductions in cataplexy attacks in people with narcolepsy type 1 (NT1), according to results from the phase 3 SYMPH
- The FDA Approves a Once-Daily Medication for Treating Hyperphagia Caused by Prader-Willi Syndromehttps://practicalneurology.com/news/the-fda-approves-a-once-daily-medication-for-treating-hyperphagia-caused-by-prader-willi-syndrome/2473822/The Food and Drug Administration (FDA) has approved Vykat XR (diazoxide choline [DCCR] extended-release tablets; Soleno, Redwood City, CA) for the treatment of hyperphagia in people with Prader-Willi syndrome (PWS) aged 4 years and older. Vykat XR is an extended-release formulation of DCCR, a cry
- Soliris Now Approved to Treat Children with Generalized Myasthenia Gravishttps://practicalneurology.com/news/soliris-now-approved-to-treat-children-with-generalized-myasthenia-gravis/2473804/The Food and Drug Administration (FDA) has approved the expansion of the indication of Soliris (eculizumab; Alexion Pharmaceuticals, Boston, MA) to now include treatment for pediatric patients aged ≥6 years with anti-acetylcholine receptor (AChR) antibody positive generalized myasthenia gravis
- FDA Approves Tenecteplase Treatment for Acute Ischemic Strokehttps://practicalneurology.com/news/fda-approves-tenecteplase-treatment-for-acute-ischemic-stroke/2473803/TNKase (Tenecteplase; Genentech, South San Francisco, CA) has received approval from the Food and Drug Administration (FDA) for the treatment of adults with acute ischemic stroke. TNKase is a tissue plasminogen activator, thrombolytic agent that is administered as a single 5-second intravenous (I
- Radiprodil Designated a Breakthrough Therapy for GRIN-Related Neurodevelopmental Disorderhttps://practicalneurology.com/news/radiprodil-designated-a-breakthrough-therapy-for-grin-related-neurodevelopmental-disorder/2473793/Radiprodil (GRIN Therapeutics, New York, NY), a selective, potent negative allosteric modulator of the N-methyl-D-aspartate receptor subtype SB (NR2B or GluN2B), has been granted Breakthrough Therapy designation by the Food and Drug Administration (FDA) for the treatment of seizures associated wi